Learn about Cystic Fibrosis (CF), also known as mucoviscidosis, diagnosis codes, clinical documentation requirements, and healthcare management. Find information on CF genetic testing, pulmonary function tests, and other diagnostic criteria. This resource provides insights for healthcare professionals on proper medical coding for CF and best practices for documenting patient care related to cystic fibrosis complications and treatment.
Also known as
Cystic fibrosis
Inherited disorder affecting mucus and sweat glands.
Cystic fibrosis with pulmonary manifestations
CF with lung involvement, like infections and breathing difficulty.
Other cystic fibrosis
CF with manifestations not classified elsewhere.
Cystic fibrosis, unspecified
CF without further specification of manifestations.
Follow this step-by-step guide to choose the correct ICD-10 code.
Is the diagnosis Cystic Fibrosis?
When to use each related code
| Description |
|---|
| Inherited disorder affecting mucus and sweat glands. |
| Bronchiectasis with chronic mucus production, not CF. |
| Chronic obstructive pulmonary disease. |
Incorrect ICD-10-CM code assignment (e.g., using E84.x instead of E84.0 for unspecified CF) impacts reimbursement and data accuracy.
Insufficient documentation of CF severity (mild, moderate, severe) affects accurate code selection and quality reporting.
Missing or inaccurate coding of CF-related complications (e.g., pulmonary infections, diabetes) leads to underreporting of disease burden.
Q: What are the most current best practices for diagnosing cystic fibrosis in newborns and infants, considering both sweat chloride testing and genetic screening?
A: Diagnosing cystic fibrosis (CF) in newborns and infants involves a two-tiered approach. First, newborn screening programs utilize immunoreactive trypsinogen (IRT) levels. Elevated IRT prompts further investigation with a second IRT test or, preferably, genetic analysis for CFTR mutations. If either the second IRT is also elevated or the genetic analysis identifies one or two CF-causing mutations, a sweat chloride test is performed to confirm the diagnosis. A sweat chloride concentration of 60 mmol/L or greater on two separate occasions is diagnostic of CF. In infants with positive newborn screening results, early diagnosis is crucial for prompt initiation of treatment to improve outcomes. Consider implementing a standardized diagnostic pathway in your practice for timely and accurate CF diagnosis. Explore how early diagnosis and intervention can significantly impact long-term pulmonary function and nutritional status in patients with CF.
Q: How can clinicians differentiate between cystic fibrosis and other respiratory conditions with similar symptoms, like asthma or chronic bronchitis, in pediatric patients?
A: Differentiating cystic fibrosis (CF) from other respiratory conditions like asthma or chronic bronchitis in children requires a thorough clinical evaluation. While symptoms like chronic cough, wheezing, and recurrent respiratory infections may overlap, CF presents with distinct features. These can include failure to thrive, meconium ileus in newborns, persistent Pseudomonas aeruginosa infections, and pancreatic insufficiency. A detailed family history of CF or related conditions should be taken. Pulmonary function tests (PFTs) often reveal an obstructive pattern in CF, but unlike asthma, they typically do not respond significantly to bronchodilators. Sweat chloride testing remains the gold standard for CF diagnosis, distinguishing it from other respiratory diseases. Learn more about the specific diagnostic criteria for CF to accurately differentiate it from conditions with similar presentations and avoid misdiagnosis. Explore resources that compare and contrast CF with other common pediatric respiratory illnesses.
Patient presents with symptoms consistent with cystic fibrosis (CF), also known as mucoviscidosis. Clinical findings include chronic productive cough, recurrent respiratory infections, and evidence of pancreatic insufficiency. The patient reports a history of failure to thrive and frequent, bulky, foul-smelling stools. Physical examination reveals crackles and wheezing on pulmonary auscultation, digital clubbing, and abdominal distension. Sweat chloride test results are elevated, confirming the diagnosis of CF. Genetic testing revealed the presence of CFTR gene mutations, further supporting the diagnosis. Differential diagnoses considered included asthma, bronchiectasis, and primary ciliary dyskinesia. Treatment plan includes airway clearance techniques such as chest physiotherapy and postural drainage, inhaled bronchodilators and mucolytics, pancreatic enzyme replacement therapy (PERT), and nutritional counseling. Patient education regarding pulmonary hygiene, infection prevention, and medication adherence was provided. Prognosis and potential complications, including CF-related diabetes and liver disease, were discussed. Referral to a CF specialist center is recommended for ongoing multidisciplinary care and management. ICD-10 code E84.0 is documented for cystic fibrosis. CPT codes for sweat chloride test, genetic testing, and pulmonary function tests are also documented for medical billing purposes. Continued monitoring of pulmonary function, nutritional status, and overall health is essential.